RxDoctor Payments Data

Bradley Jones, MD

Internal Medicine · Irving, TXNPI 1902824147

Payments from drug & device makers

$5,669in general payments, 2019–2025

Across 56 payments — averaging $101.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Sanofi-aventis U.S. LLC$250
  • Astellas Pharma US Inc$150
  • E.r. Squibb & Sons, L.L.C.$111
  • Itamar Medical Inc$99
  • plus $304 from 8 others

What the payments were for

  • Consulting fees$1,20021%
  • Speaking & faculty fees$3,20056%
  • Food & beverage$1,26922%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,669 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$193,031
Medicare patients
165
Services billed
7,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin133$139,712
MounjaroTirzepatide68$115,305
EliquisApixaban70$77,141
MyrbetriqMirabegron50$30,779
Repatha SureclickEvolocumab35$28,935
OzempicSemaglutide11$17,418
GemtesaVibegron18$15,104
JanuviaSitagliptin Phosphate11$10,022
Icosapent Ethyl21$8,308
NexlizetBempedoic Acid/Ezetimibe13$8,234
Humalog Kwikpen U-200Insulin Lispro12$7,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,115
Celecoxib225$6,536
Ezetimibe129$6,275
Xtampza ErOxycodone Myristate12$6,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$32$115,30568 claims
PfizerEliquis$21$77,14170 claims
Astellas Pharma US IncMyrbetriq$150$30,77950 claims
GSKTrelegy Ellipta, Arnuity Ellipta$43$9,57323 claims
AstraZenecaSymbicort$26$4,33411 claims
AbbVieSynthroid$56$3,33638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →